RSS-Feed abonnieren
DOI: 10.1055/s-0040-1720953
Yttrium-90 Radiation Segmentectomy
Superselective transarterial radioembolization, or radiation segmentectomy, is a novel curative-intent therapy for patients with localized hepatocellular carcinoma (HCC). Radiation segmentectomy was developed as a means of addressing two concerns in the treatment of patients with HCC. First, by selectively treating the tumor-bearing hepatic Couinaud segments, the dose of radiation to normal parenchyma is limited and, consequently, the toxicity of radiation segmentectomy is minimized. Second, selective treatment allows for utilization of a higher dose of radiation, which correlates with a higher likelihood of objective response. Radiation segmentectomy hinges on a vital physical property of yttrium-90 (90Y): the average penetration of the β-radiation emitted by the decaying 90Y is 2.5 mm in tissue.[1] This allows the radiation to be confined to the perfused volume of tumor-bearing liver in which the 90Y microspheres are deposited by the catheter, while the rest of the liver remains radiation naive. Additionally, the microembolic nature of 90Y microspheres (compared with particles used in chemoembolization) allows for maintaining arterial patency, and avoids tissue ischemia and postembolization syndrome. Radiation segmentectomy may be performed in a subsegmental fashion or, as Riaz et al originally described, ablative radioembolization may be used to treat more than one segment.[2]
Disclosure
G.E.J. is a consultant for Boston Scientific Corporation and Genentech. S.A.P. is a consultation for Boston Scientific Corporation and Bristol Meyer Squibb.
Publikationsverlauf
Artikel online veröffentlicht:
11. Dezember 2020
© 2020. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA